Trial · NCT07344779
Registered outcomes66
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 40 of 66
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Medical History per cohort and per country | at baseline | The medical history will be documented at study start. |
| Secondary | Medical History per cohort in all countries | at baseline | The medical history will be documented at study start. |
| Secondary | Concomitant medication per cohort and per country | up to 4 years | Documentation of Concomitant medication. |
| Secondary | Concomitant medication per cohort in all countries | up to 4 years | Documentation of Concomitant medication. |
| Secondary | Concomitant treatment per cohort and per country | up to 4 years | Documentation of Concomitant treatments. |
| Secondary | Concomitant treatment per cohort in all countries | up to 4 years | Documentation of Concomitant treatments. |
| Secondary | Darolutamide use per cohort and per country | up to 4 years | To describe real-world use of darolutamide in mHSPC patients. |
| Secondary | Darolutamide use per cohort in all countries | up to 4 years | To describe real-world use of darolutamide in mHSPC patients. |
| Secondary | Diagnostic Imaging Technology per cohort and per country | at baseline | Documentation of Diagnostic Imaging Technology at the initial study visits (baseline). |
| Secondary | Diagnostic Imaging Technology per cohort in all countries | at baseline | Documentation of Diagnostic Imaging Technology at the initial study visits (baseline). |
| Secondary | Adverse events per cohort and per country | up to 4 years | Number of all adverse events. |
| Secondary | Adverse events per cohort in all countries | up to 4 years | Number of all adverse events. |
| Secondary | Serious Adverse events per cohort and per country | up to 4 years | Number of all serious adverse events. |
| Secondary | Serious Adverse events per cohort in all countries | up to 4 years | Number of all serious adverse events. |
| Secondary | Drug-related Adverse events per cohort and per country | up to 4 years | Number of all drug-related (darolutamide) adverse events. |
| Secondary | Drug-related Adverse events per cohort in all countries | up to 4 years | Number of all drug-related (darolutamide) adverse events. |
| Secondary | Serious Drug-related Adverse events per cohort and per country | up to 4 years | Number of all serious drug-related (darolutamide) adverse events. |
| Secondary | Serious Drug-related Adverse events per cohort in all countries | up to 4 years | Number of all serious drug-related (darolutamide) adverse events. |
| Secondary | Adverse events leading to treatment discontinuation per cohort and per country | up to 4 years | Number of adverse events leading to treatment discontinuation. |
| Secondary | Adverse events leading to treatment discontinuation per cohort in all countries | up to 4 years | Number of adverse events leading to treatment discontinuation. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07344779/registered?page=2